Aktiesnakken — September 2010
-
-
genmab strategi
-
non-event?
-
Cost cutting med 20% i 2011
-
neurosearch tilgang til early R&D aftaler
-
synes bestemt det er nogle interessant tanker de har gjort sig. Men nej her og nu mangler vi det afgørende nyheder
-
Det ser jo ikke ud til der er kommet en guidens fremadrettet andet end udgifterne vil falde med 20%
-
20% udgiftsfald svarer så i store træk til solsens og mine regneark. Man skal lige regne det efter, men de kan så muligvis blive tæt på
-
profitable
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind